Левофлоксацин в ступенчатой терапии внебольничной пневмонии у взрослых

1. Страчунский Л.C., Розенсон О.Л. Ступенчатая терапия: новый подход к применению антибактериальных препаратов. Клин, фармакол. и тер. 1997; 6: 15-24.

2. Bartlett J.G. Respiratory tract infections. 3rd ed. Philadelphia: Lippincott W illiam s & W ilkins; 2001.

3. Davis R., Bryson H.M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700.

4. File T.M., Sergeti J., Player R. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and /or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 1997; 41: 1965-1972.

5. Fine M.J., Auble T.E., Yealy D. M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. M ed. 1997; 336: 243-250.

6. Fish D.N., Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 1997; 32: 101-119.

7. Guidelines for the management of adults w ith communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730-1754.

8. Kahn J.B., Wiesinger A., Olson W.H. et al. Levofloxacin vs. ceftriaxone sodium and erythromycin in the treatment of patients with community-acquired pneumonia at high risk of mortality [abstract P I 15]. In: Abstracts of 7th International Symposium on N ew Quinolones. Edinburgh, U K; 2001. 45.

9. Ramirez J.A. Switch therapy in community-acquired pnemonia. Diagn. Microbiol. Infect. Dis. 1995; 22: 219-223.